The Clinical Core of the UCLA ADRC is a critical vehicle for implementing the Center's theme of the Therapeutic Imperative, augmenting UCLA's ability to perform cutting edge research into identifying the causes of, and improving our ability to diagnose and treat Alzheimer's disease and other dementias. The Clinical Core serves as a link between populations at risk for various forms of dementia and research.
Specific aims of the Core are to 1) characterize persons with MCI, AD, non-AD dementias and controls, 2) characterize familial and presymptomatic Familial AD 3) retain and follow subjects longitudinally, 4) increase minority representation in dementia research, 5) provide reliable and valid data to the DMSC and to the NACC, 6), support other ADRC cores and projects, and 7) support other dementia research projects outside of the ADRC. In this proposal, we extend our abilities to achieve these goals through several new initiatives. We anticipate increasing our overall capacity to assess patients and enroll them into the NACC database with a goal of performing 130 new UDS assessments and 180 follow-up visits per year by the end of the funding period. We are making the characterization of biomarkers of AD a priority with innovative imaging studies and the acquisition of plasma, DNA, and CSF on all consenting subjects for banking for collaborative studies. We are expanding our abilities to characterize the nature, causes and ways of assessing cognitive impairment in the Hispanic elderly by increasing our presence at the Olive View Medical Center that serves a largely Hispanic population. New, highly sensitive cognitive assessment tools are being studied in the Neuropsychology Laboratory. By performing pioneering, comprehensive assessments of persons with or at-risk for FAD, we extend our understanding of AD into the presymptomatic period Persons in the FAD cohort being studied at UCLA are largely of Mexican origin, providing an opportunity to assess the utility of cognitive measures in the diagnosis of AD in this population. We have initiated new operating procedures that include safeguards insuring that appropriate informed consent is obtained prior to data entry.

Public Health Relevance

Estimates indicate that 13.2 million people in the U.S. will have AD by 2050. Despite our increased understanding of causes of AD, effective treatments for preventing or slowing it are currently lacking. The UCLA ADRC Clinical Core endeavors to enhance the development of such treatments by linking persons with or at-risk for dementia with clinical studies designed to advance this field..

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016570-14
Application #
8450820
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
14
Fiscal Year
2013
Total Cost
$429,810
Indirect Cost
$75,420
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Teng, Edmond; Chow, Nicole; Hwang, Kristy S et al. (2015) Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord 39:154-66
Hsiao, Julia J; Lu, Po H; Grill, Joshua D et al. (2015) Longitudinal declines in instrumental activities of daily living in stable and progressive mild cognitive impairment. Dement Geriatr Cogn Disord 39:24-Dec
Deutsch, Mariel B; Mendez, Mario F; Teng, Edmond (2015) Interactions between traumatic brain injury and frontotemporal degeneration. Dement Geriatr Cogn Disord 39:143-53
Sanchez-Juan, Pascual; Ghosh, Pia M; Hagen, Jayne et al. (2014) Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology 82:230-8
Burggren, Alison; Brown, Jesse (2014) Imaging markers of structural and functional brain changes that precede cognitive symptoms in risk for Alzheimer's disease. Brain Imaging Behav 8:251-61
Ringman, John M; Goate, Alison; Masters, Colin L et al. (2014) Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. Curr Neurol Neurosci Rep 14:499
Ringman, John M; Sachs, Michael C; Zhou, Yan et al. (2014) Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol 71:878-83
Grill, Joshua D; Zhou, Yan; Karlawish, Jason et al. (2014) Does study partner type impact the rate of Alzheimer's disease progression? J Alzheimers Dis 38:507-14
Ma, Qiu-Lan; Zuo, Xiaohong; Yang, Fusheng et al. (2014) Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J Neurosci 34:7124-36
Apostolova, Liana G; Di, Li Jie; Duffy, Erin L et al. (2014) Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dement Geriatr Cogn Disord 37:315-26

Showing the most recent 10 out of 476 publications